Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome, Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fortrea Holdings Inc. (FTRE) and Immunome (IMNM). ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMNM	$22.34	-7.84%	2.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMNM	$22.34	-7.8%	2.70M
3
4
5
6

IMNM

Get Immunome, Inc. Data in Excel

Get Immunome, Inc. Data in Excel